These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
216 related articles for article (PubMed ID: 31240687)
1. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Rheumatoid Arthritis: A Population-Based Cohort Study. Klil-Drori AJ; Santella C; Tascilar K; Yin H; Aprikian A; Azoulay L Drug Saf; 2019 Aug; 42(8):1005-1011. PubMed ID: 31240687 [TBL] [Abstract][Full Text] [Related]
2. Androgen Deprivation Therapy for Prostate Cancer and the Risk of Venous Thromboembolism. Klil-Drori AJ; Yin H; Tagalakis V; Aprikian A; Azoulay L Eur Urol; 2016 Jul; 70(1):56-61. PubMed ID: 26138040 [TBL] [Abstract][Full Text] [Related]
3. Different androgen deprivation therapies might have a differential impact on cognition - An analysis from a population-based study using time-dependent exposure model. Hong JH; Huang CY; Chang CH; Muo CH; Jaw FS; Lu YC; Chung CJ Cancer Epidemiol; 2020 Feb; 64():101657. PubMed ID: 31918180 [TBL] [Abstract][Full Text] [Related]
4. Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Wu CT; Yang YH; Chen PC; Chen MF; Chen WC Osteoporos Int; 2015 Sep; 26(9):2281-90. PubMed ID: 25990353 [TBL] [Abstract][Full Text] [Related]
5. Androgen deprivation therapy for prostate cancer and the risk of hospitalisation for community-acquired pneumonia. Hicks BM; Yin H; Bladou F; Ernst P; Azoulay L Thorax; 2017 Jul; 72(7):596-597. PubMed ID: 27986803 [TBL] [Abstract][Full Text] [Related]
6. Androgen deprivation therapy and risk of rheumatoid arthritis in patients with localized prostate cancer. Yang DD; Krasnova A; Nead KT; Choueiri TK; Hu JC; Hoffman KE; Yu JB; Spratt DE; Feng FY; Trinh QD; Nguyen PL Ann Oncol; 2018 Feb; 29(2):386-391. PubMed ID: 29267861 [TBL] [Abstract][Full Text] [Related]
7. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer. Nguyen C; Lairson DR; Swartz MD; Du XL Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934 [TBL] [Abstract][Full Text] [Related]
8. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. Lapi F; Azoulay L; Niazi MT; Yin H; Benayoun S; Suissa S JAMA; 2013 Jul; 310(3):289-96. PubMed ID: 23860987 [TBL] [Abstract][Full Text] [Related]
9. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Crawley D; Garmo H; Rudman S; Stattin P; Häggström C; Zethelius B; Holmberg L; Adolfsson J; Van Hemelrijck M Int J Cancer; 2016 Dec; 139(12):2698-2704. PubMed ID: 27557616 [TBL] [Abstract][Full Text] [Related]
10. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537 [TBL] [Abstract][Full Text] [Related]
11. Retrospective cohort study of androgen deprivation therapy and the risk of diabetes in men with prostate cancer in Lithuania. Drevinskaite M; Patasius A; Kincius M; Urbonas V; Smailyte G BMJ Open; 2021 Jul; 11(7):e045797. PubMed ID: 34321292 [TBL] [Abstract][Full Text] [Related]
12. Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer. Khosrow-Khavar F; Rej S; Yin H; Aprikian A; Azoulay L J Clin Oncol; 2017 Jan; 35(2):201-207. PubMed ID: 27870566 [TBL] [Abstract][Full Text] [Related]
13. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Hu JC; Williams SB; O'Malley AJ; Smith MR; Nguyen PL; Keating NL Eur Urol; 2012 Jun; 61(6):1119-28. PubMed ID: 22336376 [TBL] [Abstract][Full Text] [Related]
14. Androgen-deprivation therapy and the risk of stroke in patients with prostate cancer. Azoulay L; Yin H; Benayoun S; Renoux C; Boivin JF; Suissa S Eur Urol; 2011 Dec; 60(6):1244-50. PubMed ID: 21908097 [TBL] [Abstract][Full Text] [Related]
15. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142 [TBL] [Abstract][Full Text] [Related]
16. Androgen deprivation therapy and cardiovascular risk: No meaningful difference between GnRH antagonist and agonists-a nationwide population-based cohort study based on 2010-2013 French Health Insurance data. Scailteux LM; Vincendeau S; Balusson F; Leclercq C; Happe A; Le Nautout B; Polard E; Nowak E; Oger E Eur J Cancer; 2017 May; 77():99-108. PubMed ID: 28390298 [TBL] [Abstract][Full Text] [Related]
17. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Guo Z; Huang Y; Gong L; Gan S; Chan FL; Gu C; Xiang S; Wang S Prostate Cancer Prostatic Dis; 2018 Nov; 21(4):451-460. PubMed ID: 29988099 [TBL] [Abstract][Full Text] [Related]
18. Androgen deprivation therapy for prostate cancer and risk of dementia. Robinson D; Garmo H; Van Hemelrijck M; Damber JE; Bratt O; Holmberg L; Wahlund LO; Stattin P; Adolfsson J BJU Int; 2019 Jul; 124(1):87-92. PubMed ID: 30637900 [TBL] [Abstract][Full Text] [Related]
19. Association Between Androgen Deprivation Therapy and Risk of Dementia. Nead KT; Gaskin G; Chester C; Swisher-McClure S; Leeper NJ; Shah NH JAMA Oncol; 2017 Jan; 3(1):49-55. PubMed ID: 27737437 [TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy and the risk of colorectal cancer in patients with prostate cancer. Assayag J; Yin H; Benayoun S; Pollak MN; Suissa S; Azoulay L Cancer Causes Control; 2013 May; 24(5):839-45. PubMed ID: 23546609 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]